10 research outputs found
G-Protein-coupled Bile Acid Receptor 1 (GPBAR1, TGR5) agonists reduce the production of pro-inflammatory cytokines and stabilize the alternative macrophage phenotype
GPBAR1 (also known as TGR5) is a G protein-coupled receptor (GPCR), which triggers intracellular signals upon ligation by various bile acids. The receptor has been studied mainly for its function in energy expenditure and glucose homeostasis, and there is little information on the role of GPBAR1 in the context of inflammation. After a high-throughput screening campaign, we identified isonicotinamides exemplified by compound 3 as non-steroidal GPBAR1 agonists. We optimized this series to potent derivatives that are active on both human and murine GPBAR1. These agonists inhibited the secretion of the pro-inflammatory cytokines TNF-alpha and IL-12, but not the anti-inflammatory IL-10 in primary human monocytes. These effects translate in vivo, as compound 15 inhibits LPS induced TNF-alpha and IL-12 release in mice. The response was GPBAR1 dependent, as demonstrated using knockout mice. Furthermore, agonism of GPBAR1 stabilized the phenotype of the alternative, non-inflammatory, M2-like type cells during differentiation of monocytes into macrophages. Overall, our results illustrate an important regulatory role for GPBAR1 agonists as controllers of inflammation
Optimizing a Weakly Binding Fragment into a Potent RORγt Inverse Agonist with Efficacy in an in Vivo Inflammation Model
The
transcription factor RORγt is an attractive drug-target due
to its role in the differentiation of IL-17 producing Th17 cells that
play a critical role in the etiopathology of several autoimmune diseases.
Identification of starting points for RORγt inverse agonists
with good properties has been a challenge. We report the identification
of a fragment hit and its conversion into a potent inverse agonist
through fragment optimization, growing and merging efforts. Further
analysis of the binding mode revealed that inverse agonism was achieved
by an unusual mechanism. In contrast to other reported inverse agonists,
there is no direct interaction or displacement of helix 12 observed
in the crystal structure. Nevertheless, compound <b>9</b> proved
to be efficacious in a delayed-type hypersensitivity (DTH) inflammation
model in rats
Donated stool for faecal microbiota transplantation is not a drug, but guidance and regulation are needed
N/
Optimizing a Weakly Binding Fragment into a Potent RORγt Inverse Agonist with Efficacy in an in Vivo Inflammation Model
Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors
The
predominant expression of phosphoinositide 3-kinase δ
(PI3Kδ) in leukocytes and its critical role in B and T cell
functions led to the hypothesis that selective inhibitors of this
isoform would have potential as therapeutics for the treatment of
allergic and inflammatory disease. Targeting specifically PI3Kδ
should avoid potential side effects associated with the ubiquitously
expressed PI3Kα and β isoforms. We disclose how morphing
the heterocyclic core of previously discovered 4,6-diaryl quinazolines
to a significantly less lipophilic 5,6,7,8-tetrahydropyrido[4,3-<i>d</i>]pyrimidine, followed by replacement of one of the phenyl
groups with a pyrrolidine-3-amine, led to a compound series with an
optimal on-target profile and good ADME properties. A final lipophilicity
adjustment led to the discovery of CDZ173 (leniolisib), a potent PI3Kδ
selective inhibitor with suitable properties and efficacy for clinical
development as an anti-inflammatory therapeutic. <i>In vitro</i>, CDZ173 inhibits a large spectrum of immune cell functions, as demonstrated
in B and T cells, neutrophils, monocytes, basophils, plasmocytoid
dendritic cells, and mast cells. <i>In vivo</i>, CDZ173
inhibits B cell activation in rats and monkeys in a concentration-
and time-dependent manner. After prophylactic or therapeutic dosing,
CDZ173 potently inhibited antigen-specific antibody production and
reduced disease symptoms in a rat collagen-induced arthritis model.
Structurally, CDZ173 differs significantly from the first generation
of PI3Kδ and PI3Kγδ-selective clinical compounds.
Therefore, CDZ173 could differentiate by a more favorable safety profile.
CDZ173 is currently in clinical studies in patients suffering from
primary Sjögren’s syndrome and in APDS/PASLI, a disease
caused by gain-of-function mutations of PI3Kδ
Stool for fecal microbiota transplantation should be classified as a transplant product and not as a drug
Molecular basis of bacterial pathogenesis, virulence factors and antibiotic resistanc
Optimizing a Weakly Binding Fragment into a Potent RORγt Inverse Agonist with Efficacy in an in Vivo Inflammation Model
The
transcription factor RORγt is an attractive drug-target due
to its role in the differentiation of IL-17 producing Th17 cells that
play a critical role in the etiopathology of several autoimmune diseases.
Identification of starting points for RORγt inverse agonists
with good properties has been a challenge. We report the identification
of a fragment hit and its conversion into a potent inverse agonist
through fragment optimization, growing and merging efforts. Further
analysis of the binding mode revealed that inverse agonism was achieved
by an unusual mechanism. In contrast to other reported inverse agonists,
there is no direct interaction or displacement of helix 12 observed
in the crystal structure. Nevertheless, compound <b>9</b> proved
to be efficacious in a delayed-type hypersensitivity (DTH) inflammation
model in rats